[go: up one dir, main page]

FR2861300B1 - Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique - Google Patents

Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique

Info

Publication number
FR2861300B1
FR2861300B1 FR0312553A FR0312553A FR2861300B1 FR 2861300 B1 FR2861300 B1 FR 2861300B1 FR 0312553 A FR0312553 A FR 0312553A FR 0312553 A FR0312553 A FR 0312553A FR 2861300 B1 FR2861300 B1 FR 2861300B1
Authority
FR
France
Prior art keywords
prevention
preparation
treatment
metabolic syndrome
pyrazole derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0312553A
Other languages
English (en)
Other versions
FR2861300A1 (fr
Inventor
Michele Arnone
Jean Marc Herbert
Hassan Massoud Hesmati
Philip Janiak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to FR0312553A priority Critical patent/FR2861300B1/fr
Priority to FR0314763A priority patent/FR2861301B1/fr
Priority to FR0401193A priority patent/FR2861302A1/fr
Priority to FR0403252A priority patent/FR2861303A1/fr
Priority to ARP040103811A priority patent/AR047764A1/es
Priority to EP04805278A priority patent/EP1680117A2/fr
Priority to BRPI0415538-6A priority patent/BRPI0415538A/pt
Priority to CNA2004800347327A priority patent/CN1893946A/zh
Priority to PCT/FR2004/002715 priority patent/WO2005046689A2/fr
Priority to NZ547375A priority patent/NZ547375A/en
Priority to CA002543582A priority patent/CA2543582A1/fr
Priority to YUP-2006/0344A priority patent/RS20060344A/sr
Priority to ZA200604178A priority patent/ZA200604178B/xx
Priority to RU2006117790/15A priority patent/RU2357731C2/ru
Priority to JP2006536128A priority patent/JP2007509113A/ja
Priority to KR1020067009975A priority patent/KR20060100443A/ko
Priority to MEP-106/08A priority patent/MEP10608A/xx
Priority to AU2004289078A priority patent/AU2004289078A1/en
Priority to SG200809686-9A priority patent/SG149078A1/en
Priority to TW093132275A priority patent/TWI286935B/zh
Publication of FR2861300A1 publication Critical patent/FR2861300A1/fr
Priority to IL175103A priority patent/IL175103A0/en
Priority to MA28959A priority patent/MA28105A1/fr
Priority to US11/410,226 priority patent/US20070072907A1/en
Priority to NO20062369A priority patent/NO20062369L/no
Priority to ARP070104904A priority patent/AR063550A2/es
Priority to ARP070104905A priority patent/AR063551A2/es
Application granted granted Critical
Publication of FR2861300B1 publication Critical patent/FR2861300B1/fr
Priority to RU2008146936/15A priority patent/RU2008146936A/ru
Priority to US12/463,652 priority patent/US20090215755A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0312553A 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique Expired - Fee Related FR2861300B1 (fr)

Priority Applications (28)

Application Number Priority Date Filing Date Title
FR0312553A FR2861300B1 (fr) 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR0314763A FR2861301B1 (fr) 2003-10-24 2003-12-15 Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0401193A FR2861302A1 (fr) 2003-10-24 2004-02-05 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR0403252A FR2861303A1 (fr) 2003-10-24 2004-03-26 Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
ARP040103811A AR047764A1 (es) 2003-10-24 2004-10-21 Utilizacion de un derivado de pirazol para la preparacion de medicamentos utiles para la prevencion y el tratamiento de las dislipidemias y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
SG200809686-9A SG149078A1 (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
CNA2004800347327A CN1893946A (zh) 2003-10-24 2004-10-22 吡唑衍生物在制备用于预防和治疗异常脂血症以及与异常脂血症和/或肥胖有关的疾病的药物中的应用
PCT/FR2004/002715 WO2005046689A2 (fr) 2003-10-24 2004-10-22 Utilisation d’un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l’obesite
NZ547375A NZ547375A (en) 2003-10-24 2004-10-22 Use of rimonabant and an angiotensin II AT1 receptor antagonist for preparing medicaments for the prevention and the treatment of dyslipidemia and/or obesity
CA002543582A CA2543582A1 (fr) 2003-10-24 2004-10-22 Utilisation d'un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite
YUP-2006/0344A RS20060344A (sr) 2003-10-24 2004-10-22 Primena derivata pirazola za dobijanje lekova korisnih za prevenciju i lečenje dislipidemija i bolesti vezanih za dislipidemije i/ili gojaznost
ZA200604178A ZA200604178B (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
RU2006117790/15A RU2357731C2 (ru) 2003-10-24 2004-10-22 Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением
JP2006536128A JP2007509113A (ja) 2003-10-24 2004-10-22 異脂肪血症並びに異脂肪血症および／または肥満症に関連する疾患の予防および治療において有用である医用製品の調製へのピラゾール誘導体の使用
EP04805278A EP1680117A2 (fr) 2003-10-24 2004-10-22 Utilisation d'un derive du pyrazole pour la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite
MEP-106/08A MEP10608A (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
AU2004289078A AU2004289078A1 (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
BRPI0415538-6A BRPI0415538A (pt) 2003-10-24 2004-10-22 utilização de um derivado do pirazol para o preparo de medicamento úteis na prevenção e no tratamento das dislipidemias e das doenças associadas às dislipidemias e/ou à obesidade
TW093132275A TWI286935B (en) 2003-10-24 2004-10-22 Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and-or to obesity
KR1020067009975A KR20060100443A (ko) 2003-10-24 2004-10-22 이상지혈증의 예방과 치료, 및 이상지혈증 및(또는) 비만과관련된 질환의 예방과 치료를 위한 약제의 제조에있어서의 피라졸 유도체의 용도
IL175103A IL175103A0 (en) 2003-10-24 2006-04-23 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
US11/410,226 US20070072907A1 (en) 2003-10-24 2006-04-24 Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity
MA28959A MA28105A1 (fr) 2003-10-24 2006-04-24 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite
NO20062369A NO20062369L (no) 2003-10-24 2006-05-24 Anvendelse av et pyrazoldedvat for fiemstilling av medikamenter for a hindre og behandle dyslipideml og sykdommer assosiert med dyslipidemi og/eller fedme
ARP070104904A AR063550A2 (es) 2003-10-24 2007-11-05 Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad
ARP070104905A AR063551A2 (es) 2003-10-24 2007-11-05 Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y el tratamiento de las disciplinas y de las enfermedades asociadas a las dislipidemias y/o a la obesidad
RU2008146936/15A RU2008146936A (ru) 2003-10-24 2008-11-27 Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением
US12/463,652 US20090215755A1 (en) 2003-10-24 2009-05-11 Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0312553A FR2861300B1 (fr) 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique

Publications (2)

Publication Number Publication Date
FR2861300A1 FR2861300A1 (fr) 2005-04-29
FR2861300B1 true FR2861300B1 (fr) 2008-07-11

Family

ID=34400824

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0312553A Expired - Fee Related FR2861300B1 (fr) 2003-10-24 2003-10-24 Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique

Country Status (4)

Country Link
CN (1) CN1893946A (fr)
FR (1) FR2861300B1 (fr)
NO (1) NO20062369L (fr)
ZA (1) ZA200604178B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102416015B (zh) * 2011-08-23 2013-02-27 南京正宽医药科技有限公司 一种含他汀类药物的组合物及其用途
CN110237070A (zh) * 2019-05-10 2019-09-17 辽宁大学 厄贝沙坦在制备降血脂药物中的应用
CN112007156A (zh) * 2019-05-30 2020-12-01 复旦大学 大麻素受体药物在制备治疗心肌细胞坏死性凋亡药剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
CA2456606C (fr) * 2001-09-21 2010-01-26 Solvay Pharmaceuticals B.V. Derives 4,5-dihydro-1h-pyrazole presentant une activite antagoniste a cb1
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
CA2480856A1 (fr) * 2002-04-05 2003-10-23 Merck & Co., Inc. Arylamides substituee
PL375230A1 (en) * 2002-07-09 2005-11-28 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives

Also Published As

Publication number Publication date
FR2861300A1 (fr) 2005-04-29
CN1893946A (zh) 2007-01-10
NO20062369L (no) 2006-05-24
ZA200604178B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
FR2867778B1 (fr) Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
EP1971372A4 (fr) Compositions de supports a noyau hydrophobe pour l'administration d'agents therapeutiques, et procedes de preparation et d'utilisation
EP1710257A4 (fr) Derive d'acide hyaluronique et medicament contenant ce dernier
FR15C0069I2 (fr) Formulation a usage topique d'ivermectine pour le traitement de conditions dermatologiques
EP1789075A4 (fr) Substances ameliorant l'absorption destinees a l'administration de medicaments
EP1689348A4 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
FR15C0030I2 (fr) Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies
IL165532A (en) History of Aryl Carbonyl, Pharmaceutical Preparations Containing Them and Their Use in the Preparation of Medicines for the Treatment of Metabolic Disorders
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
EP1807146A4 (fr) Composition pour l'amelioration de l'efficacite d'administration de medicaments
MA27381A1 (fr) Association synergique d'un ligand de alpha-2-delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur
MA28844B1 (fr) Composition pharmaceutique comprenant de la drospirenone et de l'ethynylestradiol
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
EP1679070A4 (fr) Utilisation de l-butylphtalide dans la fabrication de medicaments destines a la prevention et au traitement de l'infarctus cerebral
EP2047853A4 (fr) Utilisation de stéroïde marin dans la préparation d'un médicament pour le traitement des lésions neuronales
GB2409069B (en) Administration of computing entities in a network
FR2861300B1 (fr) Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861301B1 (fr) Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
IL155853A0 (en) Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases
EP1537875A4 (fr) Medicament preventif/curatif pour l'arteriosclerose
EP1726313A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose
FR2792199B3 (fr) Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
EP1666046A4 (fr) Utilisation de la n-acetyl-d-aminoglycosamine pour la preparation de medicaments de traitement du cancer et des metastases
FR2882263B1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20110630